Erste Group Bank Lowers Earnings Estimates for Novartis

Novartis AG (NYSE:NVS) – Investment analysts at Erste Group Bank lowered their FY2026 earnings estimates for Novartis in a research note issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $9.01 for the year, down from their prior estimate of $9.09. The consensus estimate for Novartis’ current full-year earnings is $8.86 per share.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The business had revenue of $14.95 billion during the quarter.

NVS has been the topic of a number of other research reports. Citigroup reiterated a “buy” rating on shares of Novartis in a report on Wednesday, July 22nd. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $141.20.

Novartis Stock Up 0.3%

NVS opened at $156.80 on Tuesday. The firm has a market cap of $299.20 billion, a P/E ratio of 23.65, a PEG ratio of 2.67 and a beta of 0.45. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89. The business’s fifty day simple moving average is $153.21 and its 200 day simple moving average is $153.26. Novartis has a 52 week low of $117.54 and a 52 week high of $170.46.

Hedge Funds Weigh In On Novartis

Several large investors have recently added to or reduced their stakes in NVS. Arlington Trust Co LLC acquired a new position in Novartis in the fourth quarter worth $25,000. Archer Investment Corp lifted its position in shares of Novartis by 93.0% in the 1st quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after buying an additional 80 shares during the last quarter. Evolution Wealth Management Inc. lifted its position in shares of Novartis by 552.0% in the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock worth $26,000 after buying an additional 138 shares during the last quarter. Atlatl Advisers LLC acquired a new position in shares of Novartis in the 2nd quarter valued at about $26,000. Finally, CrossGen Wealth LLC acquired a new position in shares of Novartis in the 4th quarter valued at about $28,000. 13.12% of the stock is currently owned by institutional investors.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.